The 2025 healthcare landscape is being shaped by a combination of rising costs, evolving employee expectations, technological innovation, and breakthrough medical treatments, according to recent research gathered from nearly 300,000 health plan users.
According to CBIZ’s annual State of Healthcare report, one of the most significant cost drivers this year is the increasing popularity of GLP-1 weight loss drugs, such as semaglutide injections like Ozempic and Wegovy. While these medications were originally developed to treat type 2 diabetes, they’ve since gained rapid adoption for their effectiveness in promoting weight loss and reducing other chronic conditions, including cardiovascular risks.
